Maintenance and restoration of functions of the eye, being one of the main sense organs, is among vital issues of modern medicine.

80% of information about environment people get by visual perception. Most of the professional and everyday activities have to do with visual functions, their slackening or loss has the utmost negative effect on the quality of life.

In the structure of the eye retina (nervous tunic of the eyeball) is one of the thinnest layers, being the most complex and highly differentiated tissue. Its complex structure makes it sensitive to light, allowing to perceive color and images and to convert them into a signal being sent straight to the brain. Position of the retina behind other optic structures, direct ingress of sun rays, peculiarities of the blood supply make it vulnerable to both external (sun rays, light striking, radiation) and internal factors. The most common retinal diseases that can lead to the impaired vision or even to complete blindness include:

- Age-related macular degeneration
- Hereditary retinal dystrophies (including Retinitis pigmentosa)
- Complicated myopia
- Diabetic retinopathy

Modern methods of treatment based on the application of the known pharmaceutical substances do not lead to significant results. Usually a prognosis for a disease in these patients is unfavorable (gradual and progressive decrease in the visual functions up to blindness).

UNIQUE TECHNOLOGY


For the first time in the world medical and ophthalmological practice an unprecedented technology for restoration and treatment of retinal functions in case of different pathologies (including Macular degeneration, Retinitis pigmentosa, Diabetic retinopathy, thermal injuries, etc.) has been discovered by the team of the St. Petersburg Institute of Bioregulation and Gerontology.

The technology is based on peptide bioregulators, isolated from animal organs and tissues, such as retina, vessels, brain, thymus, epiphysis or their synthesized analogues. In case of introduction into the organism, peptides become inductors of synthesis of the specific proteins, capable of restoring tissues, damaged by a disease or with ageing. The efficiency of the conducted treatment course was evaluated according to the indices of visual acuity, electrophysiological test, eyeball image and subjective state of each patient. Improved visual functions were registered in 95% of the patients, which is absolutely unique.

DIAGNOSTICS OF VISUAL FUNCTIONS

At our Medical Centre you can undergo the full course of the necessary ophthalmological examinations:
- Examination and consultation of an ophthalmologist
- Eidoptometry with correction
- Field of vision analysis
- Glaucoma detection
- Fundoscopy with photorecording
- Diagnostics of the functional status of the lacrimal apparatus and lacrimal passages
- Electrophysiological studies of the retina

PRIORITY AREAS OF CLINICAL ADMINISTRATION OF THE PEPTIDE BIOREGULATORS IN OPHTHALMOLOGY:

-Retinitis pigmentosa
-Macular degeneration: dry and wet forms
-Recurrent post traumatic and post-inflammatory retinal degenerations
-Complex myopia
-Diabetic retinopathy
-Tapetoretinal eye degeneration

Dr. Yulia OSOKINA, Ph.D.

Head of Ophthalmology Department
Highest category in Ophthalmology

Candidate of Medical Sciences
Senior Researcher, Laboratory of Ophthalmology, St. Petersburg Institute of Bioregulation and Gerontology

Education:

Kemerovo State Medical Institute, 1993
Medical residency in "Eye diseases", 1995
Since 2008 he has been working at the Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology

Author of 55 scientific publications, including joint authorship of "Unique method for restoration of retinal functions in case of different diseases"

TREATMENT OF RETINAL PATHOLOGIES WITH PEPTIDE BIOREGULATORS



Retinitis pigmentosa

One of the main areas of expertise of our Ophthalmological department is hereditary retinal diseases and development of effective methods for their treatment.

Retinitis pigmentosa (lat. Retinitispigmentos, pigmented peripheral retinal abiotrophy, abbr. PR) is one of the most common hereditary eye diseases that cause retinal degeneration. It is characterized by the development of severe visual impairment up to complete blindness.

To date, more than 80 types of genetic mutations have been described. All of them lead to development of Retinitis pigmentosa, and this database continues expanding. According to the World Health Organization (WHO), this disease occurs in about 1.5 million people and can manifest itself in both childhood and adulthood.

As a result of many years of research, the scientists of the Institute have developed highly effective peptide complexes, which have been successfully used in the treatment of PR for many years. These peptide preparations make it possible to stop the process of deterioration of visual functions, maintain the result obtained and improve dynamics.

After several courses of individual therapy in our Medical Centre you will have the opportunity not only to stop the process of vision deterioration, but also to significantly improve your initial performance! So, for example, patients who started therapy 10-15 years ago currently demonstrate much higher results in visual tests than before treatment, although, due to the nature of the disease, they could have completely lost their sight.

It should be noted that at present there is no real affordable alternative for the treatment of Retinitis pigmentosa in the world.

We should emphasize that right after the first treatment course they reported increased visual acuity, significant widening of the fields of vision, improved scotopic (twilight) vision. With every reason we may say that there are no examples of such positive results observed after the treatment of this pathology in the world. In case a patient regularly undergoes courses of peptide bioregulators we reveal no negative dynamics of this severe pathology at all.






Age-related macular degeneration

Pathogenic pathway is influenced by oxidative stress, immune inflammations, lipidosis and hereditary background. It may also be related with smoking and elevated blood pressure.

The first changes that patients usually report are spots in front of the eyes or a decreased visual acuity. As a rule, by this time there are already manifestations in the fundus in the form of changes in the pigment epithelium, drusen, redistribution of the pigment.
Thus the importance of regular preventive examination is extremely crucial. Such examinations enable to diagnose the degeneration on early stages and take necessary remedial measures accordingly.

The use of peptide bioregulators, which have a regenerating effect on the retina, can largely restore visual functions.

This unique treatment technology allows achieving good results even in advanced cases. And in the early stages, you can completely stop the process of dystrophy. After treatment, patients note a decrease or complete disappearance of the spot before the eye, improvement in vision and color perception.

To date, preparations based on peptide bioregulators, developed at the St. Petersburg Institute of Bioregulation and Gerontology, are the most effective treatment for this pathology.